<DOC>
	<DOCNO>NCT00787852</DOCNO>
	<brief_summary>The purpose study evaluate maximum dose 100 mg dasatinib concurrent chemoradiation tolerate patient chemotherapy naive stage III NSCLC separate cohort locally advance potentially resectable disease .</brief_summary>
	<brief_title>A Study Dasatinib With Concurrent Chemoradiation Stage III Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Describe safety maintenance dasatinib , 100 mg/day 2 year , patient stage III NSCLC . For patient potentially resectable disease , assess pathologic complete response follow neoadjuvant dasatinib , paclitaxel , carboplatin 50.4 Gy concurrent radiation . For patient locally unresectable disease , obtain radiographic response data follow dasatinib , paclitaxel , carboplatin 64.8 Gy radiation .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Pathologically prove ( either histologic cytologic ) diagnosis Stage IIIA IIIB nonsmall cell lung cancer ; exclude patient N3 disease base supraclavicular contralateral hilar adenopathy , [ accord AJCC Staging , 6th edition ; see Appendix G ] within 4 week registration . No prior chemotherapy radiation lung cancer . No prior radiation malignancy within radiation field . Patients may potentially resectable unresectable . Stage III A B disease , include distant metastasis base follow diagnostic workup : History/physical examination prior registration . CT Scan chest Pet Scan within 28 day study entry . CT Scan abdomen MRI abdomen Pet Scan within 28 day study entry . An MRI brain Head CT Scan contrast within 28 day study entry . Total body PET scan within 6 week study entry highly recommend require operable patient . If PET scan perform bone scan require . A bone scan perform within 6 week study entry . A bone scan need PET scan perform . Mediastinoscopies highly recommend . Mediastinoscopy require patient undergoing PET scan operable . Patients must measurable evaluable disease . Patients postobstructive pneumonia eligible . Patients must least 3 week prior thoracotomy ( perform ) ECOG Performance Status 01 . Age &gt; 18 . Postop predict FEV1 &gt; 40 % eligible surgical resection . CBC/differential obtain within 2 week prior registration study , adequate bone marrow function define follow : Absolute neutrophil count ( ANC ) &gt; 1,500 cells/ul . Platelets &gt; 100,000 cells/ul . Hemoglobin &gt; 9.0 g/dl ( Note : The use transfusion intervention achieve Hgb &gt; g/dl acceptable . ) PT , PTT Grade 01 Serum creatinine &lt; 1.5 x ULN Total bilirubin &lt; 2.0 time institutional Upper Limit Normal ( ULN ) AST ALT &lt; 2.5 x ULN Serum Na , K+ , Mg2+ , Phosphate normal range ( LLN ) Women childbearing potential ( WOCBP ) must negative serum urine pregnancy test within 72 hour prior start study drug administration . Persons reproductive potential must agree use utilize adequate method contraception throughout treatment least 4 week study drug stop prior study enrollment , woman childbearing potential must advise importance avoid pregnancy trial participation potential risk factor unintentional pregnancy . If capable give birth father child , must agree use form birth control ( example effective birth control : condom diaphragm spermicidal jelly ; oral , injectable , implanted birth control ; abstinence ) medically acceptable study doctor take part research study . This necessary treatment involve study may significantly teratogenic . PFT 's within 8 week study entry EKG within 6 week study entry Ability take oral medication ( dasatinib must swallow whole ) Patient must sign study specific informed consent prior study entry . Patient agree discontinue St. Johns Wort receive dasatinib therapy ( discontinue St. Johns Wort least 5 day start dasatinib ) Supraclavicular disease Pleural pericardial effusion grade No prior malignancy [ one treat study ] require radiotherapy systemic treatment within past 3 year Severe , active comorbidity , define follow : Cardiac Symptoms ; follow consider exclusion : Uncontrolled angina , congestive heart failure MI within ( 6 month ) Diagnosed congenital long QT syndrome Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) Prolonged QTc interval preentry electrocardiogram ( &gt; 450 msec ) Subjects hypokalemia hypomagnesemia correct prior dasatinib administration Acute bacterial fungal infection require intravenous antibiotic time registration Acquired Immune Deficiency Syndrome ( AIDS ) base upon current CDC definition ; note , however , HIV test require entry protocol . The need exclude patient AIDS protocol necessary treatment involve protocol may significantly immunosuppressive . Protocolspecific requirement may also exclude immunocompromised patient History significant bleeding disorder unrelated cancer , include : Diagnosed congenital bleeding disorder ( e.g. , von Willebrand 's disease ) . Diagnosed acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) . Ongoing recent ( &lt; 3 month ) significant gastrointestinal bleeding Concomitant Medications , follow consider exclusion : Category I drug generally accept risk cause Torsades de Pointes include : ( Patients must discontinue drug 7 day prior start dasatinib ) : 1. quinidine , procainamide , disopyramide 2. amiodarone , sotalol , ibutilide , dofetilide 3. erythromycin , clarithromycin 4. chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide , cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious ) illness Women : unwilling unable use acceptable method avoid pregnancy entire study period least 4 week cessation study drug , positive pregnancy test baseline , pregnant breastfeed Any history allergic reaction paclitaxel taxanes , carboplatin . Uncontrolled neuropathy grade 2 great regardless cause . Patients full dose aspirin , Clopidogrel bisulfate ( plavix ) GPIIb/IIIa platelet inhibitor eligible . Patients must agent stop within 7 day initiate treatment . Patients may low dose aspirin ( 81 mg/day ) .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>dasatinib</keyword>
	<keyword>radiation</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>carboplatin</keyword>
	<keyword>NSCLC</keyword>
	<keyword>safety addition dasatinib chemo RT stage III NSCLC</keyword>
</DOC>